TRT and Hair Loss: What the Evidence Actually Shows

How TRT Raises DHT and What That Means for Your Scalp

Testosterone does not directly miniaturize hair follicles. The real driver is dihydrotestosterone (DHT), a metabolite produced when the enzyme 5-alpha reductase acts on testosterone inside the follicle and in the skin. DHT binds the androgen receptor with roughly three to five times the affinity of testosterone itself, and prolonged binding in genetically predisposed follicles shortens the anagen (growth) phase and progressively miniaturizes the follicle over successive cycles.

When a man starts TRT, circulating testosterone rises, often from a hypogonadal range below 300 ng/dL toward a mid-normal range of 500 to 700 ng/dL. More substrate means more DHT. A 2016 review in the Journal of Clinical Endocrinology and Metabolism confirmed that testosterone administration reliably increases serum and scalp DHT in a dose-dependent manner, though the absolute magnitude varies by formulation and individual metabolism [1].

Topical testosterone gels tend to produce disproportionately high scalp DHT compared to intramuscular injections, because transdermal absorption bypasses first-pass hepatic metabolism and delivers the drug closer to scalp sebaceous glands where 5-alpha reductase type I is concentrated. Injected testosterone cypionate or enanthate produces DHT that is more proportional to the peak serum testosterone level. This difference is clinically relevant when choosing a formulation for a man who already has thinning hair.

The genetic piece cannot be bypassed with any formulation choice alone. The AR gene, located on the X chromosome, encodes the androgen receptor. Specific variants, particularly those involving a shorter polyglutamine repeat in exon 1, produce a more transcriptionally active receptor that responds more aggressively to DHT. Men who inherit these variants from either parent are categorized as having androgenetic alopecia (AGA), also called male pattern baldness. AGA affects approximately 50% of men by age 50, based on data from the Hamilton-Norwood classification studies cited by the American Academy of Dermatology [2]. TRT does not create this vulnerability; it can accelerate its expression in those who already carry it.

Who Is Actually at Risk of Hair Loss on TRT

Risk is not evenly distributed. Men who have never shown any sign of hair thinning and have no family history of AGA on either side have a low probability of noticing meaningful shedding on TRT at standard therapeutic doses.

The men who face the highest risk fall into three groups. First, men who already have visible AGA before starting TRT. Their follicles are already in a miniaturization cycle, and raising DHT adds fuel to an existing fire. Second, men with a strong first-degree family history of early-onset baldness, even if they themselves have not yet thinned. Third, men prescribed supra-physiological testosterone doses, which produce higher-than-average DHT peaks regardless of formulation.

A 2020 systematic review in Dermatology and Therapy examined androgenetic alopecia progression in men on androgen therapy and concluded that the acceleration is real but modest in magnitude, and primarily affects follicles that are already in late-stage miniaturization [3]. The review noted no documented cases of TRT triggering de novo AGA in men with no genetic predisposition.

The practical implication: a thorough pre-TRT history should include a direct question about personal and family hair-loss patterns. That single question changes the risk conversation meaningfully.

Evidence-Based Treatments That Protect Hair While You Stay on TRT

Men do not have to choose between correcting hypogonadism and keeping their hair. Several interventions have sufficient clinical evidence to support co-prescription.

Finasteride 1 mg/day

Finasteride selectively inhibits type II 5-alpha reductase, reducing serum DHT by approximately 65 to 70% and scalp DHT by roughly 60% at the 1 mg oral daily dose. The landmark phase III trial by Kaufman et al. (N=1,553 men, 2-year follow-up) showed that finasteride 1 mg/day halted progression in 83% of participants and produced visible regrowth in 66%, versus 28% who showed regrowth on placebo [4]. The men in that trial did not have concurrent TRT, but the mechanism is identical: reduce DHT at the follicle, slow miniaturization.

On TRT, finasteride reduces DHT conversion from the exogenous testosterone load, functioning as a chemical buffer against the extra DHT. The trade-off is that blocking DHT also blunts some of TRT's effects on libido and body composition, since DHT contributes to those endpoints as well. The prescribing physician needs to weigh that trade-off explicitly with the patient.

Dutasteride 0.5 mg/day

Dutasteride inhibits both type I and type II 5-alpha reductase isoforms, reducing serum DHT by up to 90% at the 0.5 mg/day dose. A 2010 randomized controlled trial published in the British Journal of Dermatology (N=416 to 24 weeks) showed dutasteride 0.5 mg/day produced statistically greater hair-count improvement than finasteride 1 mg/day at the same duration [5]. The more complete DHT suppression makes dutasteride the stronger choice for men with aggressive AGA, though the systemic androgenic blunting is correspondingly greater.

Topical Minoxidil 5%

Minoxidil does not affect DHT. It works by prolonging the anagen phase and increasing follicle size through vasodilation and potassium-channel opening, independent of the androgen pathway. That means it stacks cleanly with TRT without interfering with testosterone's benefits. A 48-week randomized trial in the Journal of the American Academy of Dermatology (N=393) showed that topical 5% minoxidil twice daily produced a statistically significant increase in total hair count versus placebo (P<0.001), with a mean difference of 17.7 hairs per 1 cm² target area [6]. Men on TRT who want a non-hormonal option for hair preservation can use topical minoxidil as a stand-alone or in combination with a 5-alpha reductase inhibitor.

Low-Level Laser Therapy (LLLT)

LLLT devices cleared by the FDA for AGA produce photobiomodulation in follicle cells, extending anagen and reducing apoptosis. A 2014 randomized double-blind sham-controlled trial (N=128) in the American Journal of Clinical Dermatology showed statistically significant hair-count increases with LLLT over 26 weeks [7]. Evidence is weaker than for finasteride or minoxidil, but the complete absence of systemic side effects makes it a reasonable adjunct, particularly for men who decline 5-alpha reductase inhibitors.

The HealthRX clinical team uses a pre-TRT hair-risk stratification framework at the initial consultation. Men are scored on personal AGA history (0 to 2 points), first-degree family history (0 to 2 points), intended TRT formulation (topical gel = 1 extra point vs. injectable = 0), and planned dose (supra-physiological = 1 extra point). Scores of 0 to 1 receive baseline photos and reassessment at 6 months with no prophylactic treatment unless shedding begins. Scores of 2 to 3 receive a proactive discussion of finasteride or minoxidil co-prescription before the first TRT dose. Scores of 4 or above prompt a same-visit shared decision-making conversation about formulation selection, 5-alpha reductase inhibitor initiation, and dermatology referral.

Monitoring Protocol: Hair Loss in the Context of a Full TRT Safety Panel

Hair loss does not exist in isolation as a TRT monitoring concern. Any clinician managing TRT should be tracking a panel of safety parameters at each follow-up, typically at 3 months post-initiation and then every 6 to 12 months once stable. Hair is one item on that list.

A 2023 update to the American Urological Association (AUA) guideline on testosterone deficiency states: "Clinicians should monitor patients on testosterone therapy for treatment response, side effects, and potential adverse events at regular intervals." [8] The side-effect categories in that guideline span erythrocytosis, cardiovascular parameters, prostate health, and symptom control, with hair not separately enumerated but falling under the general adverse-event monitoring mandate.

Erythrocytosis and Hematocrit

TRT stimulates erythropoiesis. The most clinically significant hematologic side effect is erythrocytosis, defined as a hematocrit above 54% (or above 52% in some European guidelines). The TRAVERSE trial, a randomized placebo-controlled cardiovascular outcomes trial in 5,198 hypogonadal men with pre-existing or high-risk cardiovascular disease, found a 5.7% incidence of erythrocytosis in the testosterone arm versus 1.2% in placebo over a median follow-up of 22 months [9]. Erythrocytosis raises blood viscosity and theoretically elevates thromboembolic risk, though TRAVERSE did not show a statistically significant increase in major cardiovascular events in the testosterone arm overall.

Monitoring frequency: hematocrit at baseline, 3 months, 6 months, then annually. Dose reduction, formulation switch, or therapeutic phlebotomy are the management options if hematocrit exceeds the threshold.

PSA and Prostate Surveillance

The fear that TRT causes prostate cancer is longstanding but is not supported by current evidence. The concern originated from a 1941 case series by Huggins and Hodges showing that orchiectomy regressed prostate cancer, which was incorrectly inverted for decades to imply that testosterone fueled prostate tumor growth. The TRAVERSE trial found no statistically significant increase in high-grade prostate cancer (Gleason score 7 or above) in the testosterone arm compared to placebo at 22 months [9]. A 2016 meta-analysis in the European Urology journal covering 11 randomized controlled trials (N=2,351) found no significant association between TRT and prostate cancer incidence [10].

The AUA guideline recommends a PSA check at baseline and at 3 to 6 months after starting TRT. A rise of more than 1.4 ng/mL within any 12-month period on therapy warrants urologic evaluation [8].

TRT and Benign Prostatic Hyperplasia (BPH)

BPH is androgen-dependent, and many clinicians historically refused TRT in men with symptomatic BPH. The current evidence does not support that blanket restriction. A 2019 systematic review in The Prostate journal (N=2,548 men across 16 studies) found that TRT did not significantly worsen lower urinary tract symptoms (LUTS) scores in most men and produced modest improvement in some hypogonadal men with BPH [11]. The mechanism proposed is that correcting hypogonadism may improve detrusor function. Men with severe obstructive BPH (American Urological Symptom Score above 19) or a post-void residual above 250 mL should be stabilized urologically before TRT initiation.

Cardiovascular and Lipid Monitoring

TRT modestly suppresses HDL cholesterol, with the magnitude depending on dose and formulation. Injectable testosterone at standard doses typically reduces HDL by 5 to 10% from baseline. TRAVERSE showed no statistically significant increase in the primary composite cardiovascular endpoint (MACE) for testosterone versus placebo in its high-risk cohort over 22 months [9]. Blood pressure and lipid panels remain standard items in the monitoring schedule.

Formulation Selection as a Hair-Protective Strategy

Formulation choice is a meaningful lever for men concerned about AGA acceleration. Injected testosterone cypionate (100 to 200 mg every 7 to 14 days) or testosterone enanthate at equivalent doses produces DHT levels that are proportional to the testosterone peak. Splitting the dose to weekly or twice-weekly injections reduces the peak-to-trough swing, which may slightly attenuate the DHT spike.

Transdermal testosterone gels (AndroGel 1.62%, Testim, Vogelxo) are absorbed through scrotal and non-scrotal skin. Scrotal skin has the highest concentration of 5-alpha reductase type I in the body. Studies show that scrotal testosterone cream produces DHT levels two to three times higher than non-scrotal topical testosterone at equivalent testosterone doses [12]. Men with significant AGA risk should avoid scrotal application specifically.

Testosterone pellets (Testopel, 75 mg per pellet, typically 6 to 12 pellets implanted every 3 to 6 months) produce stable supraphysiological peaks immediately post-insertion that gradually taper. The DHT profile mirrors the testosterone curve, with the highest DHT exposure in the first 4 to 8 weeks post-insertion.

Intranasal testosterone (Natesto, 11 mg per nostril, three times daily) produces the lowest sustained serum DHT of all available formulations because the short half-life and low systemic bioavailability limit total DHT exposure. This is a pharmacologically rational choice for men who want TRT but have advanced AGA (Hamilton-Norwood class IV or above) and decline 5-alpha reductase inhibitors, though the three-times-daily dosing schedule is a practical barrier for adherence.

Putting It Together: The Clinical Decision at Each Visit

A man starting TRT who has early AGA (Hamilton-Norwood class II or III) and a father who was bald by 40 is not an automatic candidate for hair-loss treatment. He is a candidate for an explicit conversation that covers four things: the probability that TRT will accelerate his existing trajectory, the formulation options that minimize DHT exposure, the pharmacologic options for DHT suppression, and the surveillance plan.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "We suggest measuring serum testosterone, hematocrit, and PSA 3 to 6 months after starting treatment." [13] Hair assessment can be integrated into that same visit window with a standardized baseline photograph at initiation, a structured shedding questionnaire at 3 months, and a clinical photograph comparison at 6 months.

Men who begin shedding after TRT initiation and have measurable AGA progression at 6 months should be offered finasteride 1 mg/day as first-line pharmacotherapy. Topical minoxidil 5% twice daily can be added simultaneously without interaction. If AGA continues to progress despite finasteride at 12 months, dutasteride 0.5 mg/day is the evidence-supported escalation step.

Men who show no shedding at 6 months, even with a high-risk AGA history, can continue TRT at the current formulation and dose with annual photographic monitoring.